Forte Biosciences, Inc. (FBRX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated August 27, 2026, announces the completion of the acquisition of Forte Biosciences, Inc. by argenx BV ("Parent"). The transaction was executed via a tender offer followed by a short-form merger under Section 251(h) of the Delaware General Corporation Law, without a stockholder vote. Forte Biosciences is now a wholly-owned subsidiary of argenx BV.
Key Financial Metrics and Transaction Details
- Offer Price: $77.00 per share in cash.
- Shares Tendered: 19,894,879 shares validly tendered and not withdrawn.
- Ownership Threshold: The tendered shares, combined with shares already owned by Parent, represented approximately 87.13% of outstanding shares.
- Total Transaction Value: Approximately $2.2 billion in aggregate funds used to consummate the offer and merger.
- Funding Source: Parent's cash on hand.
- Equity Treatment: Outstanding options with exercise prices below $77.00 were cashed out for the spread; options at or above $77.00 were cancelled. Restricted Stock Units (RSUs) were converted to cash payments equal to the offer price.
Material Changes Versus Prior Period
The most significant change is the cessation of Forte Biosciences as a publicly traded independent entity. The company has been delisted from the Nasdaq Capital Market, and trading of its shares has been suspended. The company's reporting obligations under Sections 13 and 15(d) of the Exchange Act are being terminated via a Form 15 filing.
Guidance, Outlook, and Management Commentary
As the company is now a private subsidiary, no future public financial guidance or outlook is provided in this filing. The filing notes that all directors and officers of Forte Biosciences ceased their roles at the effective time of the merger. They were replaced by the directors and officers of the Purchaser (argenx BV), specifically Arjen Lemmen, Karl Gubitz, and Hemamalini (Malini) Moorthy.
Investor Verification Checklist
- Verify the final cash payment receipt for tendered shares, options, and RSUs.
- Confirm the delisting status of FBRX on the Nasdaq Capital Market.
- Review the Amended and Restated Certificate of Incorporation and Bylaws (Exhibits 3.1 and 3.2) for any residual obligations.
- Check for any appraisal rights demands filed under Section 262 of the DGCL that may affect final payout timing.